NACIONALNI REGISTAR OSOBA SA ŠEĆERNOM BOLEŠĆU CRODIAB

Similar documents
HRVAT SKI ZAVOD ZA JAVNO ZDRAVST VO Zagreb, Rockefellerova 7. KB MERKUR - SVEUČILIŠNA KLINIKA VUK VRHOVAC Dugi dol 4a, Zagreb IZVJEŠĆE ZA 2011.

PERCEPTION OF CVD RISK FACTORS BY DIFFERENT STAKEHOLDERS - DOCTORS, MEDICAL STUDENTS, GENERAL PUBLIC, POLITICIANS, JOURNALISTS Professor ŽeljkoReiner,

Središnja medicinska knjižnica

AN OVERVIEW OF THE TRENDS OF CARDIOVASCULAR DISEASES IN BIH

STANDARDIZED EDUCATIONAL PROGRAM IN PERSONS WITH TYPE 2 DIABETES ON ORAL HYPOGLYCEMIC THERAPY: EFFECTS ON GLYCEMIC CONTROL AND BODY MASS INDEX

EPIDEMIOLOGY OF OVARIAN CANCER IN CROATIA

Supplementary Table 1. Baseline Characteristics by Quintiles of Systolic and Diastolic Blood Pressures

(n=6279). Continuous variables are reported as mean with 95% confidence interval and T1 T2 T3. Number of subjects

Uloga patronažne sestre u prevenciji i liječenju šećerne bolesti

SCIENTIFIC STUDY REPORT

Diabetes Mellitus. Eiman Ali Basheir. Mob: /1/2019

Obesity Prevention and Control: Provider Education with Patient Intervention

Know Your Number Aggregate Report Single Analysis Compared to National Averages

Diabetes Mellitus: A Cardiovascular Disease

Deprivation Study. The Freiburg Study

Diabetes Guidelines in View of Recent Clinical Trials Are They Still Applicable?

Secondary prevention and systems approaches: Lessons from EUROASPIRE and EUROACTION

Patient is healthy with no chronic disease or significant risk factors [16%].

INCIDENCE OF CARDIOVASCULAR RISK FACTORS IN OBESE CHILDREN

Efficacy/pharmacodynamics: 85 Safety: 89

Serum levels of galectin-1, galectin-3, and galectin-9 are associated with large artery atherosclerotic

Association between arterial stiffness and cardiovascular risk factors in a pediatric population

The GUIDANCE study. Kamlesh Khunti University of Leicester, UK. on behalf of the GUIDANCE Study Group

Središnja medicinska knjižnica

Scientific Journal of the Faculty of Medicine in Niš 2013;30(1):21-30

RISK FACTORS OR COMPLICATIONS AND RECOMMENDED TREATMENT GOALS AND FREQUENCY OF EVALUATION FOR ADULTS WITH DIABETES

The Diabetes Link to Heart Disease

Sandra Božičević dipl. ing. med. biochem, Marijana Vučić Lovrenčić, PhD Vuk Vrhovac University Clinic, Zagreb, Croatia

Uloga obiteljskog liječnika u prepoznavanju bolesnika s neuroendokrinim tumorom

Supplementary Table 1. Patient demographics and baseline characteristics (treated patients).

Structure of Visits Persons with Diabetes in Croatian Family Practice Analysis of Reasons for Encounter and Treatment Procedures using the ICPC-2

ASSeSSing the risk of fatal cardiovascular disease

Guidelines to assist General Practitioners in the Management of Type 2 Diabetes. April 2010

Chronic Benefit Application Form Cardiovascular Disease and Diabetes

Case study for CME Diabetes up-to-date management

What s New in Bariatric Surgery?

National Collaborative Wave 2 (Wave 9): National Diabetes Prevention and Management Wave, Month 9 Diabetes Management: Diabetes Register

STROKE PATIENTS TREATED AT DEPARTMENT OF NEUROLOGY, ŠIBENIK-KNIN COUNTY GENERAL HOSPITAL,

Diabetes and Weight Management: Tools to Affect Patient Outcomes

Primary Prevention Patients aged 85yrs and over

Views of Elementary School Teachers towards Students with Cochlear Implants Inclusion in the Process of Education

Supplemental Table S2: Subgroup analysis for IL-6 with BMI in 3 groups

Difference in glucagon-like peptide-1 concentrations between C-peptide negative type 1 diabetes mellitus patients and healthy controls

American Academy of Insurance Medicine

Challenges in type 2 diabetes control: slipping control and weight gain

Diabetes and New Meds for Cardiovascular Risk Reduction. F. Dwight Chrisman, MD, FACC. Disclosures: BI Boehringer Ingelheim speaker

Type 2 diabetes in Tuvalu: A drug use and chronic disease management evaluation. Prepared for the Ministry of Health, Tuvalu.

Journal of Diabetes, Endocrinology and Metabolic Diseases

To reduce the risk of cardiovascular disease and diabetes among Oklahoma state employees.

High intensity exercise improves cardiac structure and function and reduces liver fat in adults with Type 2 diabetes

Davor Galetović, Ivana Olujić, Ljubo Znaor, Kajo Bućan, Dobrila Karlica, Mladen Lešin and Tihomir Sušac

Total risk management of Cardiovascular diseases Nobuhiro Yamada

Središnja medicinska knjižnica

Relationship of Plasma Creatine Kinase and Cardiovascular Function in Myocardial Infarction

Diabetes and Cardiovascular Risk Management Denise M. Kolanczyk, PharmD, BCPS-AQ Cardiology

FOR PERSONAL USE ONLY

Non-fasting lipids and risk of cardiovascular disease in patients with diabetes mellitus

Presenter: Lurline Less April 2018

Clinical Study Synopsis

EPIDEMIOLOGY OF PROSTATE CANCER IN CROATIA SITUATION AND PERSPECTIVES

Analysis Plan Submission Form

Diabete: terapia nei pazienti a rischio cardiovascolare

Clinical Practice Guideline Key Points

Statin therapy in patients with Mild to Moderate Coronary Stenosis by 64-slice Multidetector Coronary Computed Tomography

ESC/EAS Guidelines for the Management of Dyslipidaemias

2014/10/20. Management of Lipid Disorders Eric Klug Sunninghill, Sunward Park and CM JHB Academic Hospitals

Figure S1. Comparison of fasting plasma lipoprotein levels between males (n=108) and females (n=130). Box plots represent the quartiles distribution

Macrovascular Residual Risk. What risk remains after LDL-C management and intensive therapy?

DR WAFULA Z NALWA, MBCHB

Supplementary Appendix

Soo LIM, MD, PHD Internal Medicine Seoul National University Bundang Hospital

A replacement KAMUT khorasan wheatbased diet improves the risk profile of patients with type 2 diabetes mellitus (T2DM): a randomized cross-over trial

Type 2 diabetes how to prevent it? East of England Diabetes Mellitus Transformation and Sustainability Network 28 th March 2018

The JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009

EATING HABITS OF MALE ADOLESCENTS IN RELATION TO BMI-FOR-AGE AND PLACE OF RESIDENCE

DO CHANGING DIAGNOSTIC CRITERIA FOR GESTATIONAL DIABETES INFLUENCE PREGNANCY OUTCOME?

TUE Physician Guidelines Medical Information to Support the Decisions of TUE Committees Diabetes Mellitus DIABETES MELLITUS

The role of physical activity in the prevention and management of hypertension and obesity

Ischemic Heart and Cerebrovascular Disease. Harold E. Lebovitz, MD, FACE Kathmandu November 2010

Metabolic Syndrome and Chronic Kidney Disease

(a) y = 1.0x + 0.0; r = ; N = 60 (b) y = 1.0x + 0.0; r = ; N = Lot 1, Li-heparin whole blood, HbA1c (%)

Professional development requirements for delivery of Lift for Life

Promotive effect of comprehensive management on achieving blood glucose control in senile type 2 diabetics

Eugene Barrett M.D., Ph.D. University of Virginia 6/18/2007. Diagnosis and what is it Glucose Tolerance Categories FPG

New ESC Guidelines on Cardiovascular Disease Prevention in Clinical Practice. Lipids. Professor Željko Reiner, MD, PhD, FRCP(Lond), FESC, FACC

The State of Play of Diabetes Indicators

Izvorni znanstveni Ëlanak / Original scientific paper

Disclosures. Diabetes and Cardiovascular Risk Management. Learning Objectives. Atherosclerotic Cardiovascular Disease

Results of the liberalisation of Medisave for a population-based diabetes management programme in Singapore

ESC GUIDELINES ON DIABETES AND CARDIOVASCULAR DISEASES

METABOLIC RISK MARKERS IN WOMEN WITH POLYCYSTIC OVARIAN MORPHOLOGY

How to Reduce CVD Complications in Diabetes?

Apelin and Visfatin Plasma Levels in Healthy Individuals With High Normal Blood Pressure

Management of Diabetes in 2011: Cases

2016 EUROPEAN GUIDELINES ON CVD PREVENTION IN CLINICAL PRACTICE

INCIDENCE OF DIABETIC EYE DISEASE IN ACCORDANCE WITH DURATION, GLYCEMIC CONTROL, BLOOD AND OCULAR PRESSURE

DIABETES. A growing problem

DMEP Study Section 1 1

A pilot Study of 25-Hydroxy Vitamin D in Egyptian Diabetic Patients with Diabetic Retinopathy

Dr Aftab Ahmad Consultant Diabetologist at Royal Liverpool University Hospital Regional Diabetes Network Lead

Transcription:

IZVJEŠĆE ZA 2012. NACIONALNI REGISTAR OSOBA SA ŠEĆERNOM BOLEŠĆU CRODIAB National Diabetes Registry CroDiab 2013.

H R V AT S K I Z AV O D Z A J AV N O Z D R AV S T V O Zagreb, Rockefellerova 7. - KB MERKUR - SVEUČILIŠNA KLINIKA VUK VRHOVAC Dugi dol 4a, Zagreb IZVJEŠĆE ZA 2012. CroDiab National Diabetes Registry CroDiab Autori: Dr. sc.tamara Poljičanin, dr. med. Prof. dr. sc. Željko Metelko, dr. med. Vilma Kolarić, dipl. med. techn. Mario Šekerija, dr. med. Zagreb, 2013. HRVATSKI ZAVOD ZA JAVNO ZDRAVSTVO 2

IZVJEŠĆE ZA 2012. GODINU SAŽETAK osnovan je 2000. godine s ciljem unapređenja zdravstvene zaštite osoba sa šećernom bolešću, utvrđivanja prevalencije i incidencije šećerne bolesti i njenih akutnih i kroničnih komplikacija, praćenja morbiditeta i mortaliteta, te osnovnih kliničkih pokazatelja na nacionalnoj razini. Prijava je od 2004. godine obavezna za sve liječnike primarne i sekundarne zdravstvene zaštite koji u svojoj skrbi imaju osobe sa šećernom bolešću. U Republici Hrvatskoj, prema podacima Centralnog zdravstvenog informacijskog sustava (CEZIH), u 2012. godini registrirano je 234.457 punoljetnih osoba s dijagnozom šećerne bolesti. U CroDiab registru sveukupno je registrirano 115.149 živih bolesnika s bar jednom klasičnom prijavom u registar, a u 2012. godini pristigle su prijave za 32.572 osobe sa šećernom bolešću. Od prijavljenih bolesnika njih 6,03% klasificirano je kao tip 1, 93,02% kao tip 2, 0,87% kao drugi tip i 0,08% kao gestacijski dijabetes. 53,11% bolesnika liječeno je oralnim hipoglikemicima, 20,70% oralnim hipoglikemicima u kombinaciji s inzulinom, 24,66% samo inzulinom dok je 1,52% bolesnika liječeno samo osnovnim dijetetskim mjerama. Regulacija glikemije bila je dobra (HbA1c<6,5%) u 26,91%, granično zadovoljavajuća (6,5%<HbA1c<7,5%) u 36,23%, a loša (HbA1c>7,5%) u 36,86% bolesnika uz prosječne vrijednosti (aritmetička sredina ± standardna devijacija) HbA1c 7,29 ± 1,31, glikemije natašte 9,19 ± 2,90 te postprandijalne glikemije 11,38 ± 4,11. SUMMARY Croatian National Diabetes Registry was established in 2000 with the aim of improving health care of persons with diabetes mellitus, assessing the prevalence and incidence of diabetes mellitus and its acute and chronic complications, monitoring morbidity, mortality and other clinical care quality indicators on a national level. Since 2004, registration has been mandatory for all general practitioners and hospital physicians treating persons with diabetes mellitus. The overall number of patients registered in the CroDiab registry is 115,149, while in 2012 registrations were collected for 32,572 patients. There were 6.03% of patients with type 1 diabetes, 93.02% with type 2, 0.08% with gestational diabetes and 0.87% of those with other specific types of diabetes mellitus. Fifty-three percent of patients were treated with oral antidiabetic agents, 21% with oral antidiabetics and insulin, 24.5% with insulin alone, while 1.5% of patients were treated only with diet and physical activity. Glycemic regulation was good (HbA1c<6.5%) in 26.91% of cases, intermediate (6.5 %< HbA1c<7.5%) in 36.23% and poor (HbA1c>7.5%) in 36.86% of patients with average value (mean±standard deviation) of HbA1c being 7.29±1.31, fasting glucose 9.19±2.90, and postprandial glucose 11.38±4.11. According to the official data from Central health information system of Croatia, there were 234,457 persons with diabetes registered with their general practitioners in 2011. HRVATSKI ZAVOD ZA JAVNO ZDRAVSTVO 3

CroDiab National Diabetes Registry CroDiab Podaci Information: KB Merkur, Sveučilišna klinika Vuk Vrhovac, Zajčeva 19, Zagreb - Clinical Hospital Merkur, Vuk Vrhovac University Clinic, Dugi dol 4a, Zagreb osnovan je 2000. godine s ciljem unapređenja zdravstvene zaštite osoba sa šećernom bolešću, utvrđivanja prevalencije i incidencije šećerne bolesti i njenih akutnih i kroničnih komplikacija, praćenja morbiditeta i mortaliteta, te osnovnih kliničkih pokazatelja na nacionalnoj razini. Nacionalni registar od velikog je značaja za planiranje preventivnih akcija i redukciju troškova u zdravstvenoj zaštiti, a ne manje važna njegova uloga je i unapređenje i osiguranje kvalitetnije skrbi bolesnicima. Prijava je od 2004. godine obavezna za sve liječnike primarne i sekundarne zdravstvene zaštite koji u svojoj skrbi imaju osobe sa šećernom bolešću i koji su dužni prijaviti sve BIS podatke (Basic information sheet; definiran od Svjetske zdravstvene organizacije i Međunarodne dijabetološke federacije kao optimalan skup informacija potrebnih za praćenje i unapređenje kvalitete dijabetološke skrbi) za sve osobe sa šećernom bolešću u svojoj skrbi, svake godine jedanput. Predefinirani načini prikupljanja podataka su za dijabetološke centre - CroDiab NET aplikacijski program ili CroDiab WEB on-line sustav, a za liječnike primarne zdravstvene zaštite - CroDiab WEB on-line sustav. Korisnici kojima je nedostupno korištenje informacijske tehnologije popunjavaju papirnate BIS obrasce te ih dostavljaju poštom. Dijagnostički entiteti obuhvaćeni praćenjem definirani su prema MKB-10 klasifikaciji (E10- E14 -diabetes mellitus tip 1, tip 2, drugi, malnutricijski, nespecificirani, G63.2 - polineuropatije kod bolesti svrstanih drugamo, H36 - dijabetička retinopatija) i ICF klasifikaciji (b540 - general metabolic functions, b279 - additional sensory functions other specified and unspecified, b298 - sensory functions and pain, other specified, b2108 - seeing functions, other specified). U dinamičnom CroDiab registru sveukupno je registrirano 115.149 živih bolesnika s prijavom skupa osnovnih podataka (engl. Basic Information Sheet), a u 2012. godini pristigle su prijave za 32.572 osobe sa šećernom bolešću. Prijave su pristigle za 5.296 bolesnika iz 189 centara primarne, 11.338 bolesnika iz 13 centara sekundarne i 16.694 bolesnika iz 4 centra tercijarne zdravstvene zaštite. Od prijavljenih bolesnika njih 6,03% klasificirano je kao tip 1, 93,02% kao tip 2, 0,87% kao drugi tip i 0,08% kao gestacijski dijabetes. 53,11% bolesnika liječeno je oralnim hipoglikemicima, 20,70% oralnim hipoglikemicima u kombinaciji s inzulinom, 24,66% samo inzulinom dok je 1,52% bolesnika liječeno samo osnovnim dijetetskim mjerama. Regulacija glikemije bila je dobra (HbA1c<6,5%) u 26,91%, granično zadovoljavajuća (6,5%<HbA1c<7,5%) u 36,23%, a loša (HbA1c>7,5%) u 36,86% bolesnika uz prosječne vrijednosti (aritmetička sredina ± standardna devijacija) HbA1c 7,29 ± 1,31, glikemije natašte 9,19 ± 2,90 te postprandijalne glikemije 11,38 ± 4,11. Prosječne vrijednosti (aritmetička sredina ± standardna devijacija) ostalih najznačajnijih rizičnih faktora za razvoj kroničnih komplikacija bolesti bile su: ITM 30,00 ± 5,22 kg/m 2, sistolički krvni tlak 136,60 ± 17,19 mmhg, dijastolički krvni tlak 81,50 ± 8,80 mmhg, ukupni kolesterol 5,16 ± 1,96 mmol/l, HDL - kolesterol 1,34 ± 0,37 mmol/l, LDL - kolesterol 2,95 ± 1,11 mmol/l, trigliceridi 1,93 ± 1,71 mmol/l, a 14,48% bolesnika bili su pušači. Tijekom 2011. godine uspostavljena je razmjena podataka s bazom podataka Centralnog zdravstvenog informacijskog sustava Hrvatske (CEZIH). U Republici Hrvatskoj, prema navedenim podacima, kod izabranog obiteljskog liječnika u 2012. godini registrirano je 234.457 punoljetnih osoba s dijagnozom šećerne bolesti (E10-E14). HRVATSKI ZAVOD ZA JAVNO ZDRAVSTVO 4

Slika Figure 1. Broj godišnje prijavljenih bolesnika u CroDiab registru - Number of patients annually registered in the CroDiab Registry Slika - Figure 2. Broj bolesnika u registru na kraju godine - Number of patients in the CroDiab Registry at the end of the year Slika - Figure 3. Regulacija glikemije prema HbA1c udio bolesnika - Regulation of glycaemia according to HbA1c percentage of patients HRVATSKI ZAVOD ZA JAVNO ZDRAVSTVO 5

Tablica - Table 1. Indikatori šećerne bolesti - Diabetes indicators EPIDEMIOLOGIJA ŠEĆERNE BOLESTI EPIDEMIOLOGY OF DIABETES Incidencija tip 1 šećerne bolesti, dob 0-14 godina Annual incidence of Type 1 Diabetes by age/100,000 population 0-14 yrs Prevalencija šećerne bolesti Prevalence of diabetes mellitus/1,000 population Prevalencija oštećene tolerancije glukoze (poremećene glukoze na tašte) Prevalence of persons with impaired glucose tolerance Ispitivanje HES_data 1995-2003 (female/male per year) Ispitivanje HES_ data 1997 8.87/100000 djevojčica/godinu 8.47/100000 dječaka/godinu 65,49/1000 (dob 18-65) ( 89/1000 dob 20-80) Ispitivanje HES_ data 1997 45/1000 (dob 18-65) RIZIČNI FAKTORI ZA RAZVOJ KOMPLIKACIJA (U OSOBA SA ŠEĆERNOM BOLEŠĆU) RISK FACTORS FOR COMPLICATIONS (IN PEOPLE WITH DIABETES) HbA1c: Udio bolesnika s vrijednostima u posljednjih 12 mjeseci HbA1c: Percent tested in last 12 months HbA1c: Udio bolesnika s HbA1c >7,5% u posljednjih 12 mjeseci - HbA1c: Percent >7.5% in last 12 months Lipidi: Udio bolesnika s profilom lipida u posljednjih 12 mjeseci - Lipids: Percent with lipid profile in last 12 months Lipidi: Udio bolesnika s vrijednostima ukupnog kolesterola >4,5 mmol/l Lipids: Percent of those tested with total cholesterol >4.5 mmol/l Lipidi: Udio bolesnika s vrijednostima LDL >2.5 mmol/l Lipids: Percent with LDL >2.5 mmol/l Lipidi: Udio bolesnika s vrijednostima HDL <1.00 mmol/l Lipids: Percent with HDL <1.00 mmol/l Lipidi: Udio bolesnika s vrijednostima triglicerida >1.7 mmol/l Lipids: Percent with triglycerides >1.7 mmol/l Mikroalbuminurija: Udio bolesnika testiranih u posljednjih 12 mjeseci Microalbuminuria: Percent tested in last 12 months Mikroalbuminurija: Udio bolesnika s mikroalbuminurijom u posljednjih 12 mjeseci Microalbuminuria_ Percent with microalbuminuria in last 12 months Krvni tlak: Udio bolesnika s vrijednostima u posljednjih 12 mjeseci Blood pressure: Percent tested in last 12 months Krvni tlak: Udio bolesnika s RR>130/80 u posljednjih 12 mjeseci Blood pressure: Percent with BP >130/80 in last 12 months Udio bolesnika koji puše Percent of persons with diabetes who are smoking Udio bolesnika s ITM 25 kg/m 2 ( 30 kg/m 2 ) Percent with BMI 25 kg/m 2 ( 30 kg/m 2 ) 35,00% 39,43% 44,26% 75,90% 70,70% 15,59% 54,41% 5,40% 24,13% 52,40% 57,49% 12,05% 84,48% (41,17%) HRVATSKI ZAVOD ZA JAVNO ZDRAVSTVO 6